drugset / Trial / NCT00768911
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Rationale: In light of the demonstrated activity of anti-angiogenesis agents in rGBM, it is reasonable to postulate that adding these agents to standard RT and chemotherapy in the up-front management of newly diagnosed GBM may improve the clinical benefit. This study will examine the safety and tolerability of adding CT-322 to the standard radiation therapy/temozolomide (RT/TMZ) backbone of treatment for newly diagnosed GBM
Timeline
- Start
- 2008-10
- Primary completion
- 2010-10
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGDINETANIB | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |
| Subject | PEGDINETANIB | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | PEGDINETANIB | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |